Peptide Sciences: The Rise and Fall of a Grey Market Staple
Peptide Sciences operated from 2015 until March 2026 as one of the largest research peptide vendors in the United States. For nearly eleven years, they occupied a position that most grey market suppliers never reach: trusted default. Their retatrutide offering—sold in 5 mg, 10 mg, and 20 mg lyophilized vials—drew researchers who valued consistency over savings. The company spent years building a reputation on professional packaging, sealed vials with rubber stoppers that resealed cleanly, and labelling that looked like it came from a licensed pharmacy. None of that was an accident. Peptide Sciences understood that researchers would pay a premium for the feeling of a regulated supply chain, even when no actual regulation existed.
But reputation and reality diverged in ways that only became visible when independent testing platforms started grading batches. The story of Peptide Sciences retatrutide is a cautionary tale about trusting brand recognition over laboratory data. This review covers the full picture: what the COAs actually said, what third-party testing revealed, what the pricing meant in context, how the company compared to competitors like Onyx and Modern Aminos, and why the company shut down with a three-line notice on March 6, 2026. If you are evaluating historical vendor performance or trying to understand what went wrong, the evidence is straightforward and uncomfortable.
COA Quality — What Peptide Sciences Published vs. What Third Parties Found
Peptide Sciences posted Certificates of Analysis for every product batch on their website. The COAs for retatrutide consistently reported purity of 98% or higher by High-Performance Liquid Chromatography, with identity confirmed by Mass Spectrometry. On the surface, this looks exactly like the documentation a serious researcher would demand. The COAs carried laboratory letterhead, listed batch numbers, included UV chromatograms and MS spectra, and matched the three-document standard that responsible vendors follow: synthesis report, HPLC trace, and MS confirmation.
The problem is that those COAs came from the same laboratories Peptide Sciences contracted and paid. Independent testing told a very different story. Finnrick, an independent peptide testing platform that launched in late 2025, ran their own analysis on Peptide Sciences retatrutide samples collected from real customer orders. The results showed an E rating — the lowest grade on Finnrick’s scale. That E rating reflected actual failures: quantity discrepancies where vials contained less retatrutide than the label stated, and at least one batch where the peptide identity itself did not match the claimed compound.
Janoshik Analytical, the established European testing lab, ran 37 samples of Peptide Sciences retatrutide collected between December 2024 and March 2026. Multiple samples received failing grades. One sample was flagged as counterfeit. Not degraded. Not low-purity. Counterfeit — meaning the vial did not contain retatrutide at all. This is not a dispute about whether 97% purity is acceptable versus 99%. This is a fundamental failure of quality control for a vendor that marketed itself as premium.
Pricing — What You Actually Paid Per Milligram
Peptide Sciences retatrutide pricing sat at the high end of the grey market throughout their operation. For comparison:
- 5 mg vial: Peptide Sciences charged approximately $69–$79 ($13.80–$15.80/mg)
- 10 mg vial: Approximately $99–$129 ($9.90–$12.90/mg)
- 20 mg vial: Approximately $179–$219 ($8.95–$10.95/mg)
These prices placed Peptide Sciences above most domestic competitors. Onyx Research sold 10 mg retatrutide at $89 during the same period. Modern Aminos offered 10 mg vials at $75. Xcel Peptides ran 10 mg at $85. The premium Peptide Sciences charged — roughly 15% to 40% above competitors — was justified by the company’s reputation for rigorous testing. At least, that was the pitch.
The cruel irony is that researchers were paying more and getting less. Independent testing from Finnrick and Janoshik found that Peptide Sciences vials were frequently under-dosed. A vial labelled 10 mg might contain 7 mg or 8 mg of actual retatrutide. On a per-milligram basis, that means researchers paying $12.90/mg for labelled 10 mg were actually paying $16–$18/mg for the real peptide content they received. The value calculation flips completely. You were not buying premium quality at a premium price. You were buying inconsistent quality at inflated prices.
Industry analysis from Q1 2026 tracked 148 retatrutide observations across five vendors with a median price of $6.37/mg. Peptide Sciences sat at roughly double that median — and delivered batches that independent labs failed. The pricing did not reflect the product.
The Finnrick Rating — What E Grade Actually Means for Retatrutide
Finnrick grades vendors on a scale from A (highest) to E (lowest) based on identity confirmation, quantity accuracy, purity, and endotoxin levels. Peptide Sciences retatrutide scored an E. To understand why that matters, you need to know what the other grades looked like. Peptide Sciences semaglutide scored an A. Peptide Sciences BPC-157 scored an A. Their retatrutide scored an E. The same vendor, the same manufacturing process, the same COA documentation — and one specific product failed catastrophically while others passed.
This pattern suggests that Peptide Sciences did not have a general quality problem. They had a retatrutide problem. The compound is more difficult to synthesize than semaglutide or BPC-157 because of its triple agonist structure — a 39-amino acid peptide with a C20 fatty diacid chain attached. Eli Lilly’s Phase 3 TRIUMPH-1 trial, published May 21, 2026, showed 28.3% mean weight loss at the 12 mg dose over 80 weeks, confirming retatrutide as the most potent metabolic compound in clinical development. Compounds with this level of clinical significance attract grey market demand, but synthesizing them reliably at research grade requires manufacturing discipline that Peptide Sciences could not maintain. The Finnrick data indicates that Peptide Sciences either sourced their retatrutide from a different manufacturer than their other peptides, or their internal production process could not reliably produce the compound at the claimed purity level.
One sample that Finnrick tested in June 2025 had its score revised upward from 6.3 to 8.3 after the missing batch identifier was resolved — but that still falls short of passing grades. The batch number identified on that test was missing from the original submission, and the correction only brought the score to 8.3 out of a possible 10. Independent testing platforms like Finnrick and Janoshik do not have a financial incentive to fabricate low scores. Their entire business model depends on credibility with the research community. When they flag a batch as failed, the evidence is in the chromatogram, not in a marketing claim.
Shipping and Customer Service — The Operational Side
Peptide Sciences offered US domestic shipping with delivery typically taking 3–5 business days. Orders shipped from their facility with tracking numbers and standard insulated packaging. International shipping was available to select countries but came with longer transit times and no cold-chain guarantees. For a compound like retatrutide that requires storage at -20°C or below during transit to maintain stability, the absence of temperature-controlled shipping was a genuine weakness. Even the best lyophilized peptide will degrade if it sits in a warm delivery truck for four days.
Customer service followed a pattern familiar to anyone who has dealt with grey market vendors. Responses were slow — sometimes taking 48 to 72 hours for a reply. The company maintained a strict no-refund, no-return policy. Replacement vials were offered only in cases where visible damage occurred during shipping, and even then, the process required photographic evidence and multiple follow-up emails. Community forums like Reddit’s r/Peptides recorded recurring complaints about unresponsive support during December 2025 and January 2026, when order volumes likely spiked around the holiday season.
The most telling customer service failure happened during the shutdown itself. On March 6, 2026, Peptide Sciences posted a three-sentence notice on their homepage announcing they were ceasing operations. No warning. No system for handling pending orders. No forwarding plan for backorders. Customers who had placed orders days earlier received nothing — no product, no refund, and no reply to support tickets. The company simply vanished from its own website. That is not how a reputable vendor handles a business closure.
Peptide Sciences vs. Onyx, Modern Aminos, and Xcel
Comparing Peptide Sciences to its competitors requires separating what the company promised from what it actually delivered. The competitors who filled the gap after Peptide Sciences left the market fall into three distinct categories, each with a different approach to pricing, testing transparency, and customer protection.
Onyx Research operated in a similar price bracket but maintained A and B ratings on Finnrick testing for their retatrutide batches. Their COAs come from Janoshik Analytical directly — not from a vendor-contracted lab — which removes the conflict of interest that plagued Peptide Sciences documentation. Onyx’s 10 mg vials at $89 gave researchers a lower per-mg cost and verified purity.
Modern Aminos took the discount position, offering 10 mg retatrutide at $75 with batch-specific COAs published on their product pages. Their testing grades fluctuated between B and C on Finnrick — not perfect, but honest about where the quality sat. Modern Aminos did not pretend to be premium. Their positioning was straightforward: decent quality at a decent price.
Xcel Peptides competed directly with Peptide Sciences on the premium positioning. Xcel’s retatrutide pricing at $85 for 10 mg was lower than Peptide Sciences, and their Finnrick grades settled at B+, reflecting consistent identity confirmation and quantity accuracy within acceptable tolerances. Xcel also offered a replacement policy for failed COA verification, which Peptide Sciences never matched.
The hierarchy is clear. Peptide Sciences charged premium prices for a product that independent testing rated as the worst among major US vendors. Onyx offered the best combination of verified quality and pricing. Modern Aminos served the budget-conscious researcher who accepted some variance. Xcel provided the premium experience that Peptide Sciences claimed to deliver but did not.
The March 2026 Shutdown — What Actually Happened
The shutdown was not a single event. It was the culmination of three converging pressures that made continued operation impossible, each one building on the others until the company’s legal and operational position became untenable.
First, FDA enforcement against grey market peptide vendors accelerated dramatically in late 2025. Federal agencies moved past civil warning letters to criminal referrals, with individuals tied to grey-market peptide distribution securing guilty pleas. For a business with an estimated $7.4 million monthly revenue run rate, the personal legal risk shifted from theoretical to imminent.
Second, Eli Lilly and Novo Nordisk increased litigation targeting grey market suppliers of their patented GLP-1 compounds. Retatrutide is a Lilly compound (LY3437943). Semaglutide belongs to Novo Nordisk. Peptide Sciences carried both. Legal exposure from two pharmaceutical companies with massive legal budgets created a dual-front threat that no grey market vendor could withstand indefinitely.
Third, independent quality testing revealed that Peptide Sciences retatrutide was failing across multiple batches collected over more than a year. The Finnrick and Janoshik data became harder to ignore as more samples were tested and more failures recorded. A vendor whose business model depends on trust cannot survive when independent evidence shows their flagship products do not contain what the label claims.
HHS Secretary RFK Jr. announced on March 16, 2026, that 14 of the 19 peptides the FDA had previously banned would return to legal compounding. BPC-157, TB-500, and other popular peptides would soon be available through licensed pharmacies. But that announcement came too late for Peptide Sciences, and retatrutide was not one of the 14 compounds included. The grey market for triple agonists remains unregulated, which makes choosing a reliable vendor even more consequential.
Final Verdict — What the Evidence Says
Peptide Sciences retatrutide was overpriced and under-delivered. The company’s own COAs showed 98%+ purity, but independent testing found identity failures, quantity discrepancies, and at least one counterfeited batch across 37 samples collected over fifteen months. The E rating on Finnrick places their retatrutide at the bottom of the domestic vendor market. The $99–$129 pricing for a 10 mg vial was not justified by the product quality — it was justified by the marketing budget and eleven years of brand inertia.
For researchers currently evaluating where to source retatrutide, the lesson is specific and actionable. Do not trust a vendor’s COAs alone. Cross-reference against independent testing platforms like Finnrick or Janoshik. Compare per-milligram pricing after accounting for potential under-dosing. And understand that a vendor who tests well on semaglutide can fail catastrophically on retatrutide — the compounds are not interchangeable in difficulty of synthesis or quality control.
Peptide Sciences is gone, and the available evidence suggests they are not coming back. Several impersonator domains launched within days of the shutdown, trading on the brand recognition Peptide Sciences built over eleven years. None of them are the original company. The safest path forward is to evaluate current vendors based on what Peptide Sciences taught the community: independent testing matters more than reputation, and a premium price guarantees nothing.
Leave a Reply